BRIEF—Lead Pharma receives third milestone payment in collaboration with Sanofi

Dutch firm Lead Pharma says it has achieved the third milestone under its research collaboration with Sanofi, triggering an undisclosed payment.

The collaboration, signed in 2015, aims to develop small molecules for the treatment of a broad range of autoimmune disorders, including psoriasis, rheumatoid arthritis and inflammatory bowel disease.

The current milestone payment follows an upfront cash payment at the start of the collaboration and two milestone payments in 2015 and 2017.

Chief scientific officer Arthur Oubrie said: “We are delighted to have achieved another milestone in our collaboration, further validating the strength of our drug discovery engine and demonstrating our ability to work successfully with industry leaders like Sanofi.”